BAJAJHCARE2025-04-012025-06-30BAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses1MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses2MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses3MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses4MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses5MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses6MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses7MemberBAJAJHCARE2025-04-012025-06-30in-capmkt:OtherExpenses10MemberBAJAJHCARE2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312025-07-282025-07-22INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2025-07-2816:40:002025-07-2817:18:00Not applicablefalsefalseDuring the quarter ended 30 June 2025, there has been no default of any loan or debt securities.2025-04-012025-06-30UnauditedStandalone1488363000877700014971400006988490000107031000143562000522570005636500029382500013518890001452510000145251000023514000235140000121737000-4543000-1143000-34000000118337000187100012020800015791600053.853.75-0.11-0.113.743.640.00480.00550.0378Note <BR> 1 The above Financial Results of Bajaj Healthcare Limited the Company have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 28 July 2025 These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion <BR> 2 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year <BR> 3 The above unaudited financial results for the quarter ended 30 June 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing obligations and disclosure requirements Regulations 2015 as amended <BR> 4 The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment ie Pharmaceuticals <BR> 5 In the previous financial year ended 31 March 2024 the Board of Directors had approved to sale disposal of undertaking unit s on going concern basis situated at plot no N92 L9 3 T 30 MIDC Tarapur Taluka Boisar District Palghar Maharashtra and vacant industrial land situated at plot no D2 CH 42 and D2 CH 43 Dahej industrial area GIDC Bharuch Gujarat which were acquired under SARFAESI ACT 2022 from Saraswat Bank and plot no E62 and E63 MIDC Tarapur Taluka Boisar District Palghar Maharashtra The approval of shareholders was obtained vide postal ballot The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale the assets have been recorded at their fair value on the date these assets has been classified as held for sale Out of these one unit situated at plot number N 92 was sold during the Quarter ended 31 March 2024 The total value of assets classified as held for sale represents lower of carrying value or fair value <BR> <BR> The financial information from discontinued operations <BR> Particulars Quarter Ended Year ended <BR> 30 June 2025 31 March 2025 30 June 2024 31 March 2025 <BR> Total Income A 2.10 -37.81 6.13 58.07 <BR> Total Expenses B 47.53 50.22 118.10 459.18 <BR> Loss before Tax from Discontinued Operations C = A Less B -45.43 -88.03 -111.97 -401.11 <BR> Tax Expense or Credit from Discontinued Operations D -11.43 -46.51 -22.53 -57.78 <BR> Loss after Tax from Discontinued Operations E = C Less D -34.00 -41.52 -89.44 -343.33 <BR> <BR> 6 The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra Ordinary General Meeting EGM held on Wednesday 07 August 2024 through Video Conferencing VC Other Audio Visual Means OAVM approved the issue of 4044852 Equity Shares at Rs 338 per share including premium at Rs 333 per share to Person s belonging to non promoter category on preferential basis and the issue of convertible equity warrants 2079409 at Rs 338 per warrant including premium at Rs 333 per share to Person s belonging to promoter category as well as non promoter category on preferential basis The object of the issue is to repayment of term loan investment in capital expenditure and general corporate purpose The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd On 19 September 2024 post approval from Board the Company has allotted 3984852 number of equity shares and 2079409 convertible warrants and has also filed the relevant form with Registrar of Companies The uncalled amount of share warrants as at 30 June 2025 is Rs 5271.30 lakhs and will be received within 18 months from the allotment date of 19 September 2024. <BR> 7 The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities <BR> Particulars Rs in Lakhs <BR> Repayment and prepayment of secured or unsecured loans from bank or NBFC 15,000.00 <BR> General corporate purpose 225.90 <BR> Total 15,225.90 <BR> 8 In April 2025 the Company acquired Genrx Pharmaceuticals Private Limited in Liquidation Genrx on a going concern basis Genrx is an existing company incorporated under the provisions of the Companies Act 1956 The acquisition was made for a total consideration of Rs 1085 lakhs <BR> Subsequently on 3 June 2025 the Company filed an application with the Honourable National Company Law Tribunal NCLT Mumbai seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern Genrx has not been considered a subsidiary for consolidation purpose pending requisite approvals from the NCLT as control defined under Ind AS 110 Consolidated Financial Statements is not established <BR> 9 Previous year period figures have been regrouped to make them comparable with the current year period figures which are not material Brokerage & Commission10193000Consumption of Stores Spares and Maintainence63962000Freight Forwarding & Transport26555000Legal & Professional Expenses21609000Power and Fuel56750000Processing & Labour Charges40565000Travelling & Conveyence Expenses11634000Others62557000Items that will not be reclassified to profit or loss2500000250000062900001871000